Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much le...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Prz Gastroenterol
Главные авторы: Szymanska, Edyta, Dadalski, Maciej, Grajkowska, Wieslawa, Szymanska, Sylwia, Pronicki, Maciej, Kierkus, Jaroslaw
Формат: Artigo
Язык:Inglês
Опубликовано: Termedia Publishing House 2016
Предметы:
Original Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://ncbi.nlm.nih.gov/pubmed/28337236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2016.64746
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы